NewAmsterdam Pharma (NAMS) to Release Earnings on Wednesday

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) is anticipated to release its earnings data before the market opens on Wednesday, February 26th. Analysts expect NewAmsterdam Pharma to post earnings of ($0.48) per share for the quarter.

NewAmsterdam Pharma Price Performance

Shares of NAMS traded down $0.43 during trading hours on Friday, hitting $18.57. The company had a trading volume of 565,249 shares, compared to its average volume of 624,625. The firm has a fifty day moving average price of $23.30 and a 200-day moving average price of $20.16. NewAmsterdam Pharma has a 52-week low of $15.19 and a 52-week high of $27.29.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on NAMS shares. HC Wainwright reaffirmed a "buy" rating and issued a $48.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Royal Bank of Canada reissued an "outperform" rating and set a $40.00 price target on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. Needham & Company LLC reissued a "buy" rating and set a $36.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Finally, Scotiabank raised their price target on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a "sector outperform" rating in a research report on Wednesday, December 11th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $41.60.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 29,846 shares of the business's stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $25.54, for a total transaction of $762,266.84. Following the completion of the sale, the insider now directly owns 10,656,172 shares in the company, valued at $272,158,632.88. The trade was a 0.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last quarter, insiders sold 404,927 shares of company stock valued at $10,390,787. Company insiders own 19.50% of the company's stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.